Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab in asymptomatic or minimally symptomatic mCRPC
NCT01057810Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2010
- Primary completion
- Apr 2015
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Ipilimumab with Placebo (2 arms). Primary endpoint: Overall Survival up to 57 months. Started Jul 2010; status: completed.
02
Drugs
ipilimumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01057810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01057810.